TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB-CAMH) announced today that it intends to pursue research and development efforts on a new application derived from its core Microvolt T-Wave Alternans (MTWA) technology. The Company has gathered data, which although limited and preliminary, suggests that a variant of its core spectral analytic method of measuring Alternans may be able to identify myocardial ischemia which is otherwise largely undetected by more established cardiac diagnostic testing. Ischemia is defined as inadequate blood supply due to blockage of coronary arteries and can lead to myocardial infarction or what is commonly referred to as a “heart attack.” The Company’s current MTWA technology is focused on identifying those patients at risk for Sudden Cardiac Arrest (SCA) resulting from electrical disturbances in the heart.
